Simvastatin-ezetimibe-induced hepatic failure necessitating liver transplantation

Pharmacotherapy

Volumn 28, Issue 9, 2008, Pages 1188-1193

  Tuteja, Sony ^a   Pyrsopoulos, Nikolaos T ^a   Wolowich, William R ^a   Khanmoradi, Kamran ^a   Levi, David M ^a   Selvaggi, Gennaro ^a   Weisbaum, Geoffrey ^a   Tzakis, Andreas G ^a   Schiff, Eugene R ^a  

^a NONE

Author keywords

Adverse drug reactions; Drug induced liver failure; Ezetimibe; Hepatic failure; Liver transplantation; Simvastatin

Indexed keywords

AMINOTRANSFERASE; ESCITALOPRAM; EZETIMIBE PLUS SIMVASTATIN; SIMVASTATIN;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; CASE REPORT; DEPRESSION; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; LABORATORY TEST; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER FAILURE; LIVER TRANSPLANTATION; TREATMENT OUTCOME;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DRUG COMBINATIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; LIVER FAILURE, ACUTE; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; SIMVASTATIN;

EID: 51849089642     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.9.1188     Document Type: Article

References (29)

1. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
2. Jimenez-Alonso J, Osorio JM, Gutierrez-Cabello F, Lopez de la Osa A, Leon L, Mediavilla Garcia JD, for the Grupo Lupus Virgen de las Nieves. Atorvastatin-induced cholestatic hepatitis in a young woman with systemic lupus erythematosus. Arch Intern Med 1999;159:1811-12.
3. Nakad A, Bataille L, Hamoir V, Sempoux C, Horsmans Y. Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin. Lancet 1999;353:1763-4.
4. Graziadei IW, Obermoser GE, Sepp NT, Erhart KH, Vogel W. Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis. Lupus 2003;12:409-12.
5. Perger L, Kohler M, Fattinger K, Flury R, Meier PJ, Pauli-Magnus C. Fatal liver failure with atorvastatin. J Hepatol 2003;39:1095-7.
6. Ballare M, Campanini M, Catania E, Bordin G, Zaccala G, Monteverde A. Acute cholestatic hepatitis during simvastatin administration. Recenti Prog Med 1991;82:233-5.
7. Lata S, Chudy B. Acute cholestatic hepatitis caused by simvastatine in a 67-year-old patient [in Polish]. Przegl Lek 2006;63(suppl 7):97-8.
8. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin versus atorvastatin (VYVA) study. Am Heart J 2005;149:464-73.
9. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487-94.
10. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain national cholesterol education program adult treatment panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004;93:1481-6.
11. Ballantyne CM, Lipka LJ, Sager PT, et al. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract 2004;58:653-8.
12. Kosoglou T, Statkevich P, Johnson-Levonas AO, Paolini JF, Bergman AJ, Alton KB. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin Pharmacokinet 2005;44:467-94.
13. van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129:1748-54.
14. Prueksaritanont T, Subramanian R, Fang X, et al. Glucuronidation of statins in animals and humans: a novel mechanism of statin lactonization. Drug Metab Dispos 2002;30:505-12.
15. Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002;30:1280-7.
16. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002;301:1042-51.
17. Kiang TK, Ensom MH, Chang TK. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005;106:97-132.
18. Kosoglou T, Meyer I, Veltri EP, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol 2002;54:309-19.
19. Zhu Y, Statkevich P, Kosoglou T, et al. Effect of age on the pharmacokinetics of ezetimibe [abstract]. AAPS Pharm Sci 2000;2:2082.
20. Merck/Schering-Plough Pharmaceuticals. Zetia (ezetimibe) package insert. North Wales, PA; 2002.
21. Health Canada. Drugs and health products. Available from www.hc-sc.gc.ca/dhp-mps/index_e.html. Accessed April 30, 2006.
22. Azaz-Livshits T, Hershko A, Ben-Chetrit E. Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature. Pharmacopsychiatry 2002;35:112-15.
23. Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. Dig Dis Sci 2003;48:939-44.
24. Stewart DE. Hepatic adverse reactions associated with nefazodone. Can J Psychiatry 2002;47:375-7.
25. Lopez-Torres E, Lucena MI, Seoane J, Verge C, Andrade RJ. Hepatotoxicity related to citalopram. Am J Psychiatry 2004;161:923-4.
26. Hagley MT, Hulisz DT, Burns CM. Hepatotoxicity associated with angiotensin-converting enzyme inhibitors. Ann Pharmacother 1993;27:228-31.
27. Yeung E, Wong FS, Wanless IR, et al. Ramipril-associated hepatotoxicity. Arch Pathol Lab Med 2003;127:1493-7.
28. Gonzalez de la Puente MA, Calderon E, Espinosa R, Rincon M, Varela JM. Fatal hepatotoxicity associated with enalapril [case report]. Ann Pharmacother 2001;35:1492.
29. Jeserich M, Ihling C, Allgaier HP, Berg PA, Heilmann C. Acute liver failure due to enalapril. Herz 2000;25:689-93.